Full history for every metric is available with a Kvantra account
G Medical Innovations Holdings Ltd (GMVD)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 2 | 4 | 5 | 5 | 4 | 5 |
| Operating profit | $m | -27 | -11 | |||||
| Net profit | $m | -21 | -13 | -11 | -13 | -15 | -14 | -15 |
| EPS reported | $ | 0.00 | -45.89 | |||||
| Operating cashflow per share | $ | 0.00 | 0.00 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | 0.00 | 0.00 | |||||
| Free cash flow | $m | -21 | -12 | |||||
| Net debt | $m | 2 | 1 | |||||
| Book value equity | $m | -7 | -7 | |||||
| Book value per share | $ | 0.00 | 0.00 | |||||
| Number of shares | m | - | - | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.00 | -0.24 | |||||
| P/S LTM | x | 0.00 | 0.36 | |||||
| P/FCF LTM | x | -0.00 | -0.15 | |||||
| EV/EBITDA LTM | x | -0.06 | -0.42 | |||||
| EV/Sales LTM | x | 0.41 | 0.63 | |||||
| Earnings Yield LTM | % | 0.00% | 0.00% | |||||
| FCF Yield | % | 0.00% | -668.68% | |||||
| Quality | ||||||||
| ROE | % | 189.83% | 208.58% | |||||
| ROIC | % | 1105.7% | 1105.7% | |||||
| Operating margin | % | -620.14% | -620.14% | |||||
| Gross margin | % | 17.74% | 17.74% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -12.61% | +3.22% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -9.85 | -5.76 | |||||
| Net Debt/EBITDA | x | -0.06 | -0.06 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | - | 77.95% | |||||
| Net debt/Equity | x | -0.24 | -0.19 | |||||
| Gross debt/equity | x | -0.28 | -0.28 | |||||
Company overview
G Medical Innovations Holdings Ltd, along with its affiliated companies, operates as an early-stage commercial healthcare enterprise. It specializes in creating advanced mobile health and remote medical solutions for markets in the United States, China, and Israel. The company's product portfolio features Prizma, a user-friendly medical device that records vital signs, integrates with electronic medical records, and generates reports adhering to clinical standards. Another key offering is the Extended Holter Patch System, a multi-channel wearable biosensor designed for continuous electrocardiogram data collection for up to two weeks. Furthermore, it is developing a Wireless Vital Signs Monitoring System, intended for real-time and ongoing tracking of physiological parameters and biometrics. Beyond its devices, G Medical Innovations provides monitoring services, encompassing both independent diagnostic testing facility oversight and private patient monitoring. The company was established in 2014 and maintains its headquarters in Rehovot, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
G Medical Innovations Holdings Ltd (GMVD)
G Medical Innovations Holdings Ltd, along with its affiliated companies, operates as an early-stage commercial healthcare enterprise. It specializes in creating advanced mobile health and remote medical solutions for markets in the United States, China, and Israel. The company's product portfolio features Prizma, a user-friendly medical device that records vital signs, integrates with electronic medical records, and generates reports adhering to clinical standards. Another key offering is the Extended Holter Patch System, a multi-channel wearable biosensor designed for continuous electrocardiogram data collection for up to two weeks. Furthermore, it is developing a Wireless Vital Signs Monitoring System, intended for real-time and ongoing tracking of physiological parameters and biometrics. Beyond its devices, G Medical Innovations provides monitoring services, encompassing both independent diagnostic testing facility oversight and private patient monitoring. The company was established in 2014 and maintains its headquarters in Rehovot, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free